Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott
Rhea-AI Summary
Medtronic (NYSE: MDT) announced the U.S. commercial launch of the MiniMed 780G system integrated with the Instinct sensor, made by Abbott, on Dec 2, 2025. The system received U.S. FDA clearance earlier in 2025 to enable integration with Instinct and is now shipping nationwide.
The Instinct sensor offers up to 15 days wear and is described as the world's smallest and thinnest integrated CGM; when paired with MiniMed 780G it provides real-time glucose readings and automates insulin adjustments every 5 minutes.
Positive
- U.S. FDA clearance earlier in 2025 enabling Instinct integration
- Nationwide commercial shipping began on Dec 2, 2025
- Instinct sensor offers up to 15 days wear time
- MiniMed 780G automates insulin adjustments every 5 minutes
Negative
- None.
News Market Reaction – MDT
In the Dec 2 session, MDT declined 1.27%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Dividend declaration | Positive | -0.6% | Board approved $0.71 Q3 FY26 dividend, extending 48-year streak. |
| Dec 03 | FDA clearance | Positive | +0.0% | FDA cleared Hugo RAS for minimally invasive urologic surgeries in the U.S. |
| Dec 02 | Product launch | Positive | -1.3% | U.S. launch of MiniMed 780G system integrated with Abbott Instinct CGM. |
| Nov 18 | Earnings results | Positive | +4.7% | Q2 FY26 revenue $8.96B, EPS beat and raised organic growth, EPS guidance. |
| Nov 05 | Earnings notice | Neutral | -0.4% | Announced timetable and webcast details for Q2 FY26 earnings release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MDT has reacted strongly to earnings beats but has shown mixed or negative next-day moves around otherwise positive product and dividend announcements.
Over the past weeks, Medtronic reported strong Q2 FY26 results with revenue of $8.96B and raised guidance, which coincided with a 4.69% gain, underscoring earnings as a key driver. FDA clearance of the Hugo RAS system for urologic procedures on Dec 3, 2025 had little price impact. The same day as this MiniMed 780G and Instinct sensor U.S. launch on Dec 2, 2025, shares fell 1.27%, and the subsequent dividend declaration on Dec 4 also saw a small decline, highlighting uneven reactions to otherwise constructive news.
Key Terms
fda clearance regulatory
automated insulin delivery medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Instinct sensor is based on Abbott's most advanced CGM technology, featuring the world's smallest1,2, thinnest1, most discreet2 sensor and offers a wear time of up to 15 days. When paired with the MiniMed™ 780G system, the Instinct sensor provides real-time glucose readings which the system uses to automate insulin adjustments every five minutes, helping people with diabetes spend less time managing their condition and more time living their life.
"Bringing together the Instinct sensor, made by Abbott, with the excellent algorithm of the MiniMed™ 780G system creates an extremely effective combination. With the MiniMed™ 780G system, my patients have seen improved time in range and now with the Instinct sensor it's a seamless experience," said Dr. Steve Edelman, a person living with type 1 diabetes and founder and director of Taking Control of Your Diabetes 501c3 (TCOYD.org). "Feedback from the early customer pilot program has been very positive and matches what my colleagues and I are seeing in our clinics. I'm thrilled that the Instinct sensor is now available so that more people living with type 1 diabetes will get access to this life-changing technology improving their day-to-day experience dealing with this difficult condition."
The launch of the Instinct sensor expands Medtronic's sensor portfolio, offering more choice alongside the recently launched Simplera Sync™ sensor and the Guardian™ 4 sensor—all part of a growing ecosystem designed to make diabetes care easier and more personalized.
"This milestone marks an important next step in our work to bring the proven clinical outcomes of our MiniMed™ 780G system to more people living with diabetes," said Que Dallara, EVP and president of Medtronic Diabetes. "With this launch, we're expanding a smart dosing ecosystem built for choice, so every person can find a solution that fits their life. We exist to make life with diabetes easier and more predictable, so people living with diabetes can enjoy greater freedom and better health every day. Our goal is to deliver confidence and peace of mind, so everyone—including loved ones—can live boldly without compromise."
Learn more about the MiniMed™ 780G system paired with Instinct.
Frequently Asked Questions
Q: What is the MiniMed™ 780G system?
A: It's Medtronic's most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows and making diabetes management easier and less time-consuming.*
Q: What makes the Instinct sensor different?
A: Instinct, made by Abbott, offers up to 15 days of wear, fewer insertions, and a slim, discreet design. It's the world's smallest and thinnest integrated CGM, providing comfort and convenience without compromising accuracy.
About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
- Among patient-applied sensors.
- Data on file. Abbott Diabetes Care, Inc.
*Refers to SmartGuard™ technology. Individual results may vary.
Medtronic is a sponsorship partner of TCOYD. Dr. Steve Edelman was not compensated for his quote.
Contacts:
Ashley Patterson
Global Communications
+1 (818) 576-3025
Ryan Weispfenning
Investor Relations
+1 (763) 505-4626
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-begins-us-commercial-launch-of-the-minimed-780g-system-with-the-instinct-sensor-made-by-abbott-302629908.html
SOURCE Medtronic plc